Amgen Lung Cancer Drug Cuts Death Risk by 58%
A new drug combination from Amgen and AstraZeneca gives patients with aggressive lung cancer more time to live.
Small cell lung cancer spreads fast. Doctors struggle to treat it, and patients often run out of good options.
A new clinical trial changes that outlook. Biotech maker Amgen tested its drug Imdelltra alongside an immunotherapy from AstraZeneca. The combination cut the risk of death by 58 percent compared to standard care.
Patients on the combined treatment lived longer. The cancer also stopped growing for longer stretches of time. Amgen plans to share the full data with global health regulators.
Strong medical breakthroughs create lasting value. Major wins like this show why biotech companies remain central to long-term market growth.
Source: CNBC
More from Biotech
